期刊文献+

氯吡格雷中间体α-氯(2-氯)苯乙酸甲酯合成工艺的优化 被引量:2

Optimization of Synthetic Process of Intermediates of Clopidogrel:α-chloro-o-chlorophenylacetate
原文传递
导出
摘要 目的:探讨合成α-氯(2-氯)苯乙酸甲酯的工艺优化。方法:以邻氯扁桃酸甲酯为原料、二氯亚砜为氯化试剂合成α-氯(2-氯)苯乙酸甲酯;设计正交试验,以邻氯扁桃酸甲酯与二氯亚砜投料比、反应温度、反应时间为因素,以产率为指标优化合成工艺条件,并进行验证试验。结果:确定了最佳反应条件即邻氯扁桃酸甲酯与二氯亚砜投料比为2∶3,反应时间为1h,反应温度40℃;以此条件合成产品收率≥92%,纯度≥99%。结论:所得合成工艺条件适用于合成α-氯(2-氯)苯乙酸甲酯。 OBJECTIVE:To approach the optimization of synthetic process of α-chloro-o-chlorophenyl acetate.METHODS:α-chloro-o-chlorophenylacetate was synthesized with o-chlorophenylacetic acid and thionyl chloride.The synthetic process of α-chloro-o-chlorophenylacetate was optimized by orthogonal test with the ratio of raw materials,reaction temperature,reaction time as factors and with production efficiency as index.And the results of study were verified.RESULTS:The optimal synthesis conditions were as follows:ratio of o-chlorophenylacetic acid to thionyl chloride was equal to 2:3;the reaction time and temperature were 1 h and 40 ℃,respectively.The yield was more than 92% and purity of production was more than 99%.CONCLUSION:Established synthetic process is suitable for the synthesis of α-chloro-o-chlorophenylacetate.
出处 《中国药房》 CAS CSCD 北大核心 2010年第25期2350-2352,共3页 China Pharmacy
基金 重庆莱美药业股份有限公司对本课题的资助
关键词 α-氯(2-氯)苯乙酸甲酯 氯吡格雷 中间体 正交试验 优化 α-chloro-o-chlorophenylacetate Clopidogrel Intermediates Orthogonal test Optimization
  • 相关文献

参考文献4

二级参考文献67

  • 1姜丹.急性缺血性脑血管病早期诊断和对策[J].安徽医药,2005,9(8):624-626. 被引量:12
  • 2Anderson JL,Adams CD,Antman EM,et al.ACC/AHA2007 guidelines for the management of paints with unstable angina/non-ST-elevation myocardial infarction.J Am Coll Cardiol,2007,50(7):e1-e157
  • 3Bhatt DL,Scheiman J,Abraham NS,et al.ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use:a report of the American Documents.Circulation,2008,118(18):1894-1909
  • 4Gilard M,Arnaud B,Le Gal G,et al.Influence of omeprazol on the anpiplatelet action of clopidogroi associated to aspirin.J Thromb Hacmost,2006,4(11):2508-2509
  • 5Gilard M,Arnand B,Cornily JC,et al.Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized,doublehlind OCLA(Omeprazole CLopidogrel Aspirin)study.J Am Coll Cardiol,2008,51(3):256-260
  • 6Food and Drug Administration.Early Communication about an ongoing safety review of clopidogrel bisulfate(marketed as Plavix).http://www.fda.gov/cder/drug/early comm/clopidogrel bisulfate.htm.Accessed January 26,2009
  • 7Ho P.M,Maddox MT,Wang L et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndromes.JAMA,2009,301(9):937-944
  • 8Aubert RE,Epstein RS,Teasarden JR,et al.Abstract 3998:Proton pump inhihitors effect on clopidogrel effectiveness:the Clopidogrel Medco Outcomes Study.Circulation,2008,118(suppl.):S815
  • 9Juurlink DN,Gomes T,Ko DT,et al.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.CMAJ,2009,180(7):699-700
  • 10Geiger J,Brich J,Honig-Liedl P,et al.Specific impairment of human platelet P2Y(AC)ADP receptor2 mediated signaling by the antiplatelet drug clopidogrel.A rterioscler Thromb Vasc Biol,1999,19(8):2007-2011

共引文献56

同被引文献7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部